Find Academic Supervisors

• Alzheimer's Disease
• Neurodegenerative Diseases
• Multimodal Imaging
• +3 more

Christopher Brown serves as a Clark Scholar and instructor in the Department of Neurology at the University of Pennsylvania, where he conducts clinical training at the Penn Memory Center under Dr. Dave Wolk's mentorship. His work bridges neurology, imaging science, and neurodegenerative disease research within Penn's academic medical ecosystem. His educational trajectory includes a bachelor's degree in biology and philosophy-neuroscience-psychology from Washington University in St. Louis, followed by dual MD/PhD training at the University of Kentucky. His doctoral research focused on multimodal imaging in aging and preclinical Alzheimer's disease, specifically examining executive function decline. Dr. Brown's research centers on multimodal neuroimaging approaches to map neurodegenerative pathology propagation through white matter networks. His work integrates advanced MRI techniques with computational analysis to understand Alzheimer's disease mechanisms, emphasizing the structural connectivity basis of cognitive decline. This focus positions him at the intersection of clinical neurology and cutting-edge imaging methodology development. Analysis of his 2024-2025 publications reveals dominant themes in Alzheimer's disease genetics (particularly variant-to-function mapping in microglial models), high-resolution neuroimaging segmentation, and white matter microstructure analysis. His work consistently connects molecular mechanisms with structural brain changes, using techniques ranging from 7T MRI to multi-ancestry genetic studies. His scientific recognition includes: Clark Scholar award As a Penn Memory Center researcher, Dr. Brown contributes to collaborative projects investigating early Alzheimer's detection biomarkers. His current work extends into glymphatic system research and vascular contributions to neurodegeneration, supported by institutional resources within Penn's neuroscience infrastructure. He operates within the Penn Memory Center's research ecosystem, which integrates clinical care with translational neuroscience to advance dementia diagnosis and treatment through multidisciplinary team science.

Dmitry VelmeshevView profile

Assistant Professor

• Neurobiology
• Neurodevelopmental Disorders
• Single-Cell Genomics
• +3 more

Dmitry Velmeshev is an Assistant Professor in the Departments of Neurobiology and Biomedical Engineering at Duke University. He focuses on understanding human brain development and neurodevelopmental diseases at the single-cell level, particularly autism. His work integrates genomics, proteomics, and molecular biology to dissect genetic programs and neuronal circuitry. Ph.D., University of Miami (2016) Research interests include neurodevelopmental disorders, single-cell genomics, and molecular mechanisms of autism. Recent studies explore SARS-CoV-2 tropism for astrocytes, LRRK2 kinase activity in Parkinson’s disease, and glial roles in neurodegeneration. His lab employs transcriptomic and proteomic approaches to identify phenotypic modifiers in disease models. Selected publications highlight applications of single-cell analysis in autism and multiple sclerosis, proteomic mapping in neurodevelopmental models, and inflammation in neurodegenerative disease. No scientific awards or student advisees are mentioned in the provided text. He teaches courses such as NEUROSCI 494, NEUROSCI 493, NEUROBIO 790S, NEUROBIO 735, CMB 710F, and CMB 710E at Duke University.

Mikael SimonsView profile

Professor

• Myelin biogenesis
• CNS regeneration
• Neurodegeneration
• +6 more

Professor Mikael Simons is a distinguished neuroscientist and W3-Professor of Molecular Neurobiology at the Technical University Munich (TUM), where he serves as Director of the Institute of Neuronal Cell Biology (TUM-NCB). He is also affiliated with the German Center for Neurodegenerative Diseases (DZNE) in Munich and the Institute for Stroke and Dementia Research (ISD). His laboratory focuses on understanding the biology of glial cells and their interactions with neurons in both health and disease. Dr. Simons received his medical degree from the University of Heidelberg in 1997, where he completed his MD thesis at the Centre for Molecular Biology Heidelberg (ZMBH) with 'summa cum laude' honors. After completing his residency in Neurology at the University of Tübingen, he pursued post-doctoral studies at the Institute for Neurobiology, University of Heidelberg. He became a specialist in Neurology in 2004 and completed his Habilitation in Neurology at the University of Tübingen in 2005. His research program spans several interconnected areas of neuroscience. A primary focus is on oligodendrocytes and myelin, particularly investigating the mechanisms of myelin formation and regeneration following injury, which is highly relevant to multiple sclerosis. Another major focus is on microglia and their functions in homeostasis, aging, and disease, with particular interest in neuroinflammation mechanisms and how immune cells damage or restore nervous system function. His lab also studies the role of lipoproteins in development, regeneration, aging, and neurodegeneration within the central nervous system. Dr. Simons' laboratory employs a multidisciplinary approach combining mouse models, zebrafish, and iPSC-derived human cell systems with advanced techniques including genetics, single-cell genomics, proteomics, lipidomics, CRISPR/Cas9 gene editing, and high-resolution imaging. His team has made significant contributions to understanding myelin biogenesis, white matter aging, and the interplay between lipid metabolism and neuroinflammation. Current Positions: W3-Professor and Director, Institute of Neuronal Cell Biology, TU Munich & DZNE/Munich (2016-present) Head of Clinical Research & Clinical Trial Unit Munich at DZNE/Munich (2020-present) Scientific Awards and Honors: EMBO Young Investigator Award (2008) ERC Starting Grant (2008) ERC Consolidator Grant (2014) ERC Advanced Grant (2020) German National Academy of Sciences Leopoldina member (2023) Dr. Simons has mentored numerous graduate students and postdoctoral fellows, contributing significantly to neuroscience education and training. His laboratory is part of a vibrant research ecosystem including the Munich Excellence-Cluster for Systems Neurology (SyNergy), where he serves on the board and co-heads the electron microscopy hub. He also plays a key role in the Collaborative Research Centre 274 as its speaker and co-head of the single-cell genomics hub. The work from Dr. Simons' laboratory has important implications for understanding and treating neurodegenerative diseases, particularly those involving myelin damage such as multiple sclerosis, as well as age-related cognitive decline and dementia. His research bridges basic science with potential clinical applications, aiming to develop regenerative medicines for the nervous system.

Wei CaoView profile

Professor

• Neuroinflammation
• Alzheimer's Disease
• Neurodegenerative Diseases
• +7 more

Dr. Wei Cao is a Professor at The University of Texas Health Science Center at Houston conducting groundbreaking research at the intersection of neuroscience and immunology. His work focuses on neuroinflammation in neurodegenerative diseases, particularly Alzheimer's disease, with emphasis on the role of type I interferon pathways and microglial activation in disease pathogenesis. Dr. Cao's educational background includes a BS equivalent in Biological Science from Tsinghua University, a PhD in Biochemistry from the University of North Carolina at Chapel Hill, and postdoctoral training in Molecular Virology at The Scripps Research Institute. BS (eq) in Biological Science - Tsinghua University, Beijing, China PhD in Biochemistry - University of North Carolina at Chapel Hill Postdoctoral Fellowship in Molecular Virology - The Scripps Research Institute Dr. Cao's research program centers on understanding how neuroinflammation contributes to neurodegenerative processes, with particular focus on Alzheimer's disease. His lab discovered that type I interferon, traditionally associated with antiviral responses, plays a pathogenic role in AD by promoting synapse elimination and impairing memory performance. Current investigations explore how genomic instability and transposable element dysregulation in aging contribute to neuroinflammation, and how peripheral immune responses and environmental factors influence brain pathology. Analysis of Dr. Cao's recent publications reveals a consistent research trajectory focused on the interface between immune responses and neurodegeneration. His work spans from fundamental molecular mechanisms of interferon signaling in microglia to translational studies examining therapeutic approaches for Alzheimer's disease. The publications demonstrate expertise in both neuroscience and immunology, with increasing emphasis on the role of aging-related genomic changes in neuroinflammatory processes. Dr. Cao leads the Cao Lab and is affiliated with several research centers including the Center for Perioperative Medicine, Consortium on Aging, and Neuroscience Research Center at UTHealth Houston. His research program appears to be well-funded through multiple NIH or similar grants, though specific funding sources aren't detailed in the provided text. The lab actively investigates the connections between peripheral immune responses, environmental factors, and brain pathology in neurodegenerative conditions. Dr. Cao's laboratory is part of the broader neuroscience research ecosystem at UTHealth Houston, collaborating with researchers across multiple disciplines to understand the complex interplay between immune responses and neurodegenerative processes. His work bridges basic science and potential clinical applications, particularly in developing interventions targeting neuroinflammatory pathways in Alzheimer's disease.

Bernd WollscheidView profile

Lecturer

• Molecular Health
• Proteomics
• Cell Signaling
• +3 more

Prof. Dr. Bernd Wollscheid is a Lecturer at the Department of Health Sciences and Technology (D-HEST) at ETH Zurich, Switzerland. He leads the Wollscheid Lab and the Proteomics Plattform D-HEST , focusing on decoding the extracellular interactome and the cell surfaceome's nanoscale organization. His work bridges biology, chemistry, medicine, and bioinformatics, developing cutting-edge technologies like LUX-MS and TRICEPS-based LRC to study cellular communication and signaling pathways. Research interests include understanding how the surfaceome influences cellular functions, particularly in disease contexts such as cancer and metabolic disorders. Key projects involve creating resources like the Cell Surface Protein Atlas and PROTTER , tools for visualizing proteoforms and analyzing multi-omics datasets. His lab also explores precision medicine applications, including biomarker discovery and tumor profiling for clinical decision support. Publications highlight advancements in multi-omics integration, drug repurposing, and functional proteomics. The lab collaborates on initiatives like the Swiss Personalized Health Network (SPHN) and the Personalized Health and related Technologies (PHRT) strategic focus area. Funding comes from public grants and strategic partnerships. Recruitment for motivated researchers is ongoing, emphasizing contributions to molecular health and surfaceome research.

• Neurogenetics
• Glial Cell Biology
• Peripheral Nervous System Disorders
• +3 more

Prof. Dr. Michael Werner Sereda is a Tenured Professor of Neurology at the University of Göttingen Medical Center (UMG) and Group Leader of the Translational Neurogenetics research group at the Max Planck Institute for Multidisciplinary Sciences (MPI-NAT). His roles include leading the Neurogenetics Outpatient Clinic at UMG and coordinating national/international initiatives like CMT-NET and CMT-MODs. His research focuses on glial cell biology, axon-glia interactions, and peripheral nervous system disorders, particularly Charcot-Marie-Tooth disease type 1A (CMT1A). Key projects include developing biomarkers for disease severity and evaluating therapeutic strategies using rodent models. Research interests emphasize translational approaches, bridging basic science with clinical applications. His team has created a CMT1A transgenic rat model and identified skin-derived biomarkers now being extended to blood-based diagnostics. Collaborations like the BMBF-funded CMT-NET network aim to accelerate clinical trials for early-stage patients. Recent studies explore lipid metabolism modulation, neuregulin signaling, and ketogenic diet effects on neurodegenerative mechanisms. Prof. Sereda’s work includes over 1500 CMT patient data contributions through CMT-NET and ongoing clinical trials. His group’s biomarker studies, combined with preclinical drug testing (e.g., PXT3003), highlight the Göttingen Campus’s role as a hub for hereditary neuropathy research. Future efforts focus on pediatric CMT1A biomarkers and FDA-approved preclinical trial pathways.

Desislava M. DoychevaView profile

Academic

• Neuroscience
• Neuroinflammation
• Neonatal Brain Injury
• +4 more

Desislava M. Doycheva, PhD, is an Assistant Research Professor in the School of Medicine, jointly affiliated with the Cardiology Division (Department of Medicine) and Physiology Division (Department of Basic Sciences). Her research focuses on molecular mechanisms of neuroprotection in neonatal brain injuries, particularly hypoxic-ischemic encephalopathy (HIE) and germinal matrix hemorrhage. Dr. Doycheva's work explores signaling pathways such as AMPK/Nrf2, microglial polarization, and inflammasome regulation. Her interests include neuroinflammation mitigation, oxidative stress reduction, and developing therapies for stroke and neonatal brain injuries. She utilizes rodent models to investigate pharmacological interventions targeting apoptosis and neurodegeneration. Her recent publications emphasize neuroprotective strategies in neonatal HIE, cerebral hemorrhage, and ischemic stroke, with consistent themes in molecular pathway modulation (e.g., AMPK/Sirt1, AdipoR1, MC1R) and therapeutic timing. Research trends highlight innovations in immunotherapy, delayed recanalization, and biomarker diagnostics. Grants & Projects: Principal Investigator: 'Novel Therapeutic Strategies for Treatment of Neonatal HIE' (American Heart Association, 2020–2023) Post Doctoral Associate: 'Harness Germinal Matrix Hemorrhage' (National Institutes of Health, 2012–2017)

Martin ParentView profile

Professor

• Basal Ganglia
• Parkinson's disease
• Huntington's disease
• +6 more

Martin Parent is a Full Professor in the Department of Psychiatry and Neuroscience at the Faculty of Medicine, Laval University. His research focuses on neural circuits within the basal ganglia and their alterations in Parkinson's and Huntington's diseases. Based at the CERVO Brain Research Centre, he leads a research team that utilizes both animal models and post-mortem human brain tissue to understand neurodegenerative processes and develop potential treatments, with particular emphasis on deep brain stimulation and L-Dopa therapy mechanisms. Dr. Parent's research interests center around the anatomical and functional organization of the basal ganglia in rodents, humans, and non-human primates. His team investigates alterations in neuronal circuits that occur in Parkinson's disease and Huntington's chorea, employing a wide array of methodological approaches including in vivo electrophysiological recordings, tracer injections, three-dimensional neuron reconstructions, electron microscopy, neurotransmitter localization, and analysis of post-mortem human brain tissue. A key focus of his work is understanding how the brain adapts to the loss of dopamine neurons in Parkinson's disease, which explains the onset of dyskinesias following L-Dopa treatment. His research has highlighted the remarkable adaptability of the brain in response to neurodegeneration. Analysis of Dr. Parent's recent publications (2024-2025) reveals a strong focus on developing and applying advanced imaging techniques for deep brain stimulation surgery and neurodegenerative disease research. His work spans multiple disciplines including neuroscience, medical imaging, and biomedical engineering, with particular emphasis on Parkinson's disease mechanisms and treatments. Key trends include the application of optical imaging techniques (polarimetric imaging, Raman spectroscopy, optical coherence tomography) for brain tissue identification during neurosurgery, investigation of serotonin and other neurotransmitter systems in parkinsonian models, and exploration of neuroplasticity and cellular stress responses in neurodegenerative conditions. Dr. Parent leads the Parent Lab (http://www.parentlab.ca/), which maintains a strong collaborative network with researchers specializing in optical imaging, neurosurgery, and neurodegenerative diseases. His lab works closely with the CERVO Brain Research Centre's brain bank, an exceptional resource for studying post-mortem human brain tissue from individuals who suffered from neurodegenerative diseases. The lab's interdisciplinary approach combines expertise in neuroanatomy, electrophysiology, molecular biology, and advanced imaging techniques to address fundamental questions about basal ganglia function and dysfunction, with direct applications to improving neurosurgical procedures and developing better treatments for movement disorders.

Nathalie BerubeView profile

Professor

• Epigenetics
• Neurodevelopment
• Chromatin Remodeling
• +3 more

Dr. Nathalie Berube is a Professor in the Department of Anatomy and Cell Biology at Western University, specializing as a Basic Scientist in Pediatrics. Her research focuses on epigenetic regulation of brain development, particularly through the study of chromatin remodeling complexes like ATRX. Her work employs mouse models to explore neuronal survival, differentiation, and the molecular basis of neurodevelopmental disorders such as autism and intellectual disability. Education: Dr. Berube holds a Ph.D., though specific details of her academic training are not provided in the text. Her professional affiliations include the Medical Sciences Building and the London, Ontario campus of Western University. She contributes to both basic science and translational research in pediatric neurobiology. Research Interests: Her studies emphasize the role of ATRX protein in chromatin structure, gene transcription, and DNA methylation. Key areas include neurodevelopmental deficits, glial cell biology, and the interplay between epigenetic regulation and cognitive disorders. Her work bridges molecular mechanisms with clinical implications, such as autism spectrum disorder and intellectual disability syndromes. Publications: Over 50 peer-reviewed articles span topics from chromatin accessibility to microglial function. Notable contributions include mouse model studies of ATRX deficiency and insights into epigenetic signatures of genetic disorders. Full publication lists are accessible via Google Scholar and PubMed. Grants and Advising: While specific grants or student advisees are not detailed, her research program likely involves collaborative grants given the complexity of her experimental systems. No awards are explicitly mentioned in the provided texts. Labs/Teams: Active in the Anatomy and Cell Biology department, her lab focuses on epigenetic mechanisms in neurodevelopment. Collaborations with pediatric and genetic research groups are implied through her work on syndromes like ATRX-related intellectual disability.

Rakez KayedView profile

Professor

• Neurodegenerative Diseases
• Protein Misfolding
• Tau Oligomer Toxicity
• +4 more

Dr. Rakez Kayed is a Professor in the Department of Neurology at the University of Texas Medical Branch (UTMB) and holds the John Sealy Chair for Parkinson's Research. He leads research at the Mitchell Center for Neurodegenerative Disorders, focusing on molecular mechanisms of neurodegenerative diseases including Alzheimer's, Parkinson's, and tauopathies. His work investigates protein misfolding, tau oligomer toxicity, and immunotherapeutic approaches. Education: B.S. Chemistry, University of Jordan Ph.D. in Organic/Medicinal Chemistry, University of Tübingen Postdoctoral training in Alzheimer's and Protein Misfolding Diseases, University of California, Irvine Dr. Kayed's research explores neurodegenerative pathology, protein aggregation dynamics, and therapeutic targeting of amyloid and tau oligomers. His lab develops diagnostic biomarkers using biological samples and studies amyloid involvement in cancer, diabetes, and traumatic brain injury. Recent work emphasizes immunotherapeutic strategies to halt disease progression. His publications frequently address tau pathology propagation, oligomer toxicity, and neuroinflammation mechanisms. Articles show consistent focus on bridging basic protein biochemistry with clinical applications in neurodegeneration. Awards: Warmoth Professorship in Neurology International Society for Neurochemistry Fellowship Society for Neuroscience Award DFG Fellowship Dr. Kayed collaborates internationally and contributes to editorial boards of major neurology journals. His lab employs molecular biology, animal models, and translational approaches to advance neurodegenerative disease therapeutics.

Jeffrey MogilView profile

Professor

• Behavioral Neuroscience
• Pain Mechanisms
• Neuroimmunology
• +3 more

Jeffrey Mogil is a Professor at McGill University's Department of Psychology, holding the Canada Research Chair in Genetics of Pain (Tier I) and the E.P. Taylor Chair in Pain Studies. His research focuses on nervous system mechanisms underlying pain perception and modulation, particularly exploring variability in pain sensitivity and responses to analgesics across sexes and individuals. Mogil employs multidisciplinary approaches, including molecular genetics and behavioral neuroscience, to study social influences on pain, neuroimmune interactions, and translational pain models. Key research themes include the role of microglia in chronic pain, sex differences in pain processing, and the neurobiology of placebo/nocebo effects. He has pioneered the use of mouse grimace scales (PainFace software) for standardized pain measurement in animals. Mogil critiques methodological biases in preclinical research and advocates for inclusive sex-based analysis in biomedical studies. Key Contributions: Identified immune system contributions to chronic pain, demonstrated social modulation of pain in rodents, and advanced pain measurement techniques. Labs/Teams: Leads the MOGILab at McGill, collaborating internationally on pain genetics and neuroimmunology. Grants: Supported by Canadian Institutes of Health Research (CIHR), US National Institutes of Health (NIH), and industry partnerships.

Sonia GarelView profile

Professor

• Neuroscience
• Developmental Biology
• Neurodevelopmental Disorders
• +5 more

Sonia Garel is a Professor in the Department of Biology at the École Normale Supérieure (ENS), Paris. She leads the Brain Development and Plasticity research team, focusing on understanding how embryonic programs and maternal signals control the assembly of functional forebrain circuits. Her work integrates experimental approaches in mice to study neuronal migration, axonal navigation, and microglial roles in brain morphogenesis. Research Interests : Gael's research explores mechanisms underlying cortical circuit formation, prenatal inflammation's impact on neurodevelopmental disorders (e.g., autism, schizophrenia), and microglia's roles in structural integrity during fetal brain development. Key areas include axonal guidance (thalamic and corticothalamic connections), Cajal-Retzius neuron dynamics, and the interplay between activity-dependent processes and environmental factors. Recent Work Trends : Her publications emphasize microglia's critical role in fetal brain development, serotonergic regulation of axonal plasticity post-preterm birth, and the biphasic effects of inflammation on inhibitory circuits. Recent studies also highlight microbiome influences on microglia and sex-specific developmental pathways. Lab & Collaborations : Her team collaborates with computational biologists and uses advanced imaging techniques. The lab investigates how intrinsic developmental programs and external signals (e.g., maternal environment) shape neural circuits, with implications for neuropsychiatric disease etiology.

• Functional Genomics
• CRISPR Technology
• Stem Cell Research
• +4 more

Dr. Cesar L. Moreno is a Postdoctoral Research Associate and Dr. John and Anne Chong Genome Editing and Stem Cell Research Fellow at the School of Life and Environmental Sciences, The University of Sydney, with an adjunct appointment as Associate Lecturer at the Kirby Institute, University of New South Wales. His work focuses on developing functional genomic tools for disease modeling using stem cells and mouse models. Education: PhD in Neuroscience from Icahn School of Medicine at Mount Sinai (2015) Postdoctoral training at Gandy Lab and New York Stem Cell Foundation (2015-2017) Research at UQ-StemCARE Centre, University of Queensland (until 2020) Dr. Moreno's research centers on CRISPR-based genetic screens in stem cells to investigate diseases like COVID-19 and biological processes including neural development and ageing. He integrates functional genomic and epigenomic approaches to uncover molecular pathways in neurodegenerative disorders, metabolic diseases, and viral pathologies, with emphasis on translating findings into therapeutic strategies. His 15 most recent publications reveal a strong trajectory in genome editing technologies, stem cell disease modeling, and virology, particularly SARS-CoV-2 research. Key themes include CRISPR screening innovations, Alzheimer's disease mechanisms using iPSC models, metabolic regulation, and neuroinflammation, demonstrating consistent interdisciplinary collaboration. Scientific Awards: Ruth L. Kirschstein National Research Service Awards for Individual Predoctoral Fellows F31 (2011-2015) Travel Scholarship for Aging and Diseases of Aging Keystone Symposium, Tokyo, Japan (2012) Dr. Moreno currently supervises two research students on dementia-related projects and secured a 2022 NHMRC Ideas Grant for the "UNIVERSAL NEUROPHOTONIC INTERFACE" project. He serves as a member of the Charles Perkins Centre and leads four major research initiatives spanning CRISPR barcoding, SARS-CoV-2 pathology, circadian rhythms in brain development, and neurophotonic stem cell models.

Maria EricssonView profile

Researcher

• Electron Microscopy
• Cell Biology
• Structural Biology
• +3 more

Maria Ericsson, B.S., is the Director of the Harvard Medical School (HMS) Electron Microscopy Core within the Cell Biology Department. She joined HMS in 1995 to establish the Electron Microscopy Facility, following her B.Sc. in Chemistry from Uppsala University (Sweden) and specialization in electron microscopy at the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany. Her work focuses on advancing ultrastructural studies, providing expertise in sample preparation (TEM/SEM), high-pressure freezing, immunogold labeling, and imaging support for researchers. Ericsson collaborates extensively on projects involving Parkinson’s disease, Alzheimer’s disease, and viral pathogenesis (e.g., SARS-CoV-2). Her publications highlight contributions to neurodegenerative mechanisms, mitochondrial function, and microscopy techniques. Ongoing research emphasizes the role of electron microscopy in understanding cellular processes, protein aggregation, and immune responses. As Core Director, she supports over 89 publications, including studies on α-synuclein in Parkinson’s, amyloid-β in Alzheimer’s, and SARS-CoV-2 lung pathology. Her facility bridges technical expertise with cutting-edge research, aiding advancements in structural biology and disease modeling.

• Diabetes
• Obesity
• Metabolism
• +9 more

Suneil Koliwad, MD, PhD, is a Professor in the Department of Medicine at the University of California, San Francisco (UCSF) School of Medicine, where he serves as Chief of the Division of Endocrinology and Metabolism at UCSF Health. His research is conducted through the UCSF Diabetes Center, where he leads a laboratory investigating the intersection of nutrition, inflammation, and metabolic tissue function in obesity, diabetes, fatty liver disease, and aging. Dr. Koliwad earned his B.S. in Psychobiology from UCLA, followed by an MD and PhD in Molecular Physiology from Baylor College of Medicine. He completed residency in Internal Medicine/Pediatrics and a fellowship in Diabetes, Endocrinology, and Metabolism at UCSF, along with additional training in Diversity, Equity, and Inclusion. His research focuses on how immune cells, particularly microglia in the brain and macrophages in adipose tissue, regulate metabolic homeostasis. His lab explores mechanisms linking dietary fats to inflammation, insulin resistance, and adipose tissue fibrosis, utilizing a deeply curated multiethnic obesity cohort to translate findings into clinical contexts. Key areas include the role of DGAT1 in lipid metabolism, MFGE8-integrin signaling in insulin resistance, and microglial programming of glucose control. His recent publications highlight trends in neuroimmunometabolism, adipose tissue remodeling, and the clinical application of diabetes technology. Work in Cell Metabolism , Nature Metabolism , and JCI demonstrates a strong emphasis on molecular mechanisms of metabolic disease, with a growing focus on human cohorts and translational applications. Election to American Society of Clinical Investigation (ASCI), 2018 Distinguished Endocrinologist Award, UC Irvine, 2022 Guenther Boden, MD Memorial Award Lecture, Temple University, 2024 A.P. Giannini Scholarship, 2006 Alpha Omega Alpha Honor Society, 1998 Dr. Koliwad has been Principal Investigator on multiple NIH R01 grants, including projects on microglia, fat-associated inflammation in HIV, and myeloid lipid storage. He leads a research team that fosters collaboration across disciplines, and his lab has trained numerous postdoctoral fellows and contributed to large multi-institutional studies. His work bridges basic science with clinical endocrinology, aiming to improve the understanding and treatment of metabolic diseases.